Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER

Whether the sodium–glucose cotransporter 2 inhibitor dapagliflozin reduces the risk of a range of morbidity and mortality outcomes in patients with heart failure regardless of ejection fraction is unknown. A patient-level pooled meta-analysis of two trials testing dapagliflozin in participants with...

Descripción completa

Detalles Bibliográficos
Autores principales: Jhund, Pardeep S., Kondo, Toru, Butt, Jawad H., Docherty, Kieran F., Claggett, Brian L., Desai, Akshay S., Vaduganathan, Muthiah, Gasparyan, Samvel B., Bengtsson, Olof, Lindholm, Daniel, Petersson, Magnus, Langkilde, Anna Maria, de Boer, Rudolf A., DeMets, David, Hernandez, Adrian F., Inzucchi, Silvio E., Kosiborod, Mikhail N., Køber, Lars, Lam, Carolyn S. P., Martinez, Felipe A., Sabatine, Marc S., Shah, Sanjiv J., Solomon, Scott D., McMurray, John J. V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2022
Materias:
Analysis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9499855/
https://www.ncbi.nlm.nih.gov/pubmed/36030328
http://dx.doi.org/10.1038/s41591-022-01971-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9499855/
https://www.ncbi.nlm.nih.gov/pubmed/36030328
http://dx.doi.org/10.1038/s41591-022-01971-4

Ejemplares similares